TLRY
Tilray Brands, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$4.50
−0.66%Year over year
Reported trailing growth
- Revenue
- +1.2%
- EBITDA
- +100.5%
- EBIT
- +98.1%
- EPS
- +95.9%
- Free cash flow
- +34.8%
- Operating cash flow
- +43.2%
Forward estimates
Based on analyst estimates
- Revenue
- -1.0%
- EBITDA
- +277.6%
- EPS
- +73.5%
Three-year CAGR
- Revenue
- +2.7%
- EBITDA
- +98.7%
- EBIT
- +98.0%
- Net income
- +95.9%
- EPS
- +96.8%
- Free cash flow
- +41.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of May 1, 2026